RemeGen nets $515m from Hong Kong IPO
Chinese biopharmaceutical firm RemeGen has raised HK$3.99bn ($514.7m) after pricing its IPO at the top of the marketed range, according to a source familiar with the matter.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: